Jessica S Wallisch1,2,3, Dennis W Simon4,5,6, Hülya Bayır1,2,3,7, Michael J Bell1,2,3,8, Patrick M Kochanek1,2,3, Robert S B Clark1,2,3. 1. Department of Critical Care Medicine, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA, 15224, USA. 2. Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 3. Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 4. Department of Critical Care Medicine, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, 4401 Penn Avenue, Pittsburgh, PA, 15224, USA. dennis.simon2@chp.edu. 5. Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. dennis.simon2@chp.edu. 6. Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. dennis.simon2@chp.edu. 7. Center for Free Radical and Antioxidant Health, Department of Environmental and Occupational Health, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 8. Department of Neurological Surgery, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Abstract
BACKGROUND: Inflammasome-mediated neuroinflammation may cause secondary injury following traumatic brain injury (TBI) in children. The pattern recognition receptors NACHT domain-, Leucine-rich repeat-, and PYD-containing Protein 1 (NLRP1) and NLRP3 are essential components of their respective inflammasome complexes. We sought to investigate whether NLRP1 and/or NLRP3 abundance is altered in children with severe TBI. METHODS: Cerebrospinal fluid (CSF) from children (n = 34) with severe TBI (Glasgow coma scale score [GCS] ≤8) who had externalized ventricular drains (EVD) placed for routine care was evaluated for NLRP1 and NLRP3 at 0-24, 25-48, 49-72, and >72 h post-TBI and was compared to infection-free controls that underwent lumbar puncture to rule out CNS infection (n = 8). Patient age, sex, initial GCS, mechanism of injury, treatment with therapeutic hypothermia, and 6-month Glasgow outcome score were collected. RESULTS: CSF NLRP1 was undetectable in controls and detected in 2 TBI patients at only <24 h post-TBI. CSF NLRP3 levels were increased in TBI patients compared with controls at all time points, p < 0.001. TBI patients ≤4 years of age had higher peak NLRP3 levels versus patients >4 (15.50 [3.65-25.71] vs. 3.04 [1.52-8.87] ng/mL, respectively; p = 0.048). Controlling for initial GCS in multivariate analysis, peak NLRP3 >6.63 ng/mL was independently associated with poor outcome at 6 months. CONCLUSIONS: In the first report of NLRP1 and NLRP3 in childhood neurotrauma, we found that CSF NLRP3 is elevated in children with severe TBI and independently associated with younger age and poor outcome. Future studies correlating NLRP3 with other markers of inflammation and response to therapy are warranted.
BACKGROUND: Inflammasome-mediated neuroinflammation may cause secondary injury following traumatic brain injury (TBI) in children. The pattern recognition receptors NACHT domain-, Leucine-rich repeat-, and PYD-containing Protein 1 (NLRP1) and NLRP3 are essential components of their respective inflammasome complexes. We sought to investigate whether NLRP1 and/or NLRP3 abundance is altered in children with severe TBI. METHODS: Cerebrospinal fluid (CSF) from children (n = 34) with severe TBI (Glasgow coma scale score [GCS] ≤8) who had externalized ventricular drains (EVD) placed for routine care was evaluated for NLRP1 and NLRP3 at 0-24, 25-48, 49-72, and >72 h post-TBI and was compared to infection-free controls that underwent lumbar puncture to rule out CNS infection (n = 8). Patient age, sex, initial GCS, mechanism of injury, treatment with therapeutic hypothermia, and 6-month Glasgow outcome score were collected. RESULTS: CSF NLRP1 was undetectable in controls and detected in 2 TBI patients at only <24 h post-TBI. CSF NLRP3 levels were increased in TBI patients compared with controls at all time points, p < 0.001. TBI patients ≤4 years of age had higher peak NLRP3 levels versus patients >4 (15.50 [3.65-25.71] vs. 3.04 [1.52-8.87] ng/mL, respectively; p = 0.048). Controlling for initial GCS in multivariate analysis, peak NLRP3 >6.63 ng/mL was independently associated with poor outcome at 6 months. CONCLUSIONS: In the first report of NLRP1 and NLRP3 in childhood neurotrauma, we found that CSF NLRP3 is elevated in children with severe TBI and independently associated with younger age and poor outcome. Future studies correlating NLRP3 with other markers of inflammation and response to therapy are warranted.
Authors: Patrick M Kochanek; Nancy Carney; P David Adelson; Stephen Ashwal; Michael J Bell; Susan Bratton; Susan Carson; Randall M Chesnut; Jamshid Ghajar; Brahm Goldstein; Gerald A Grant; Niranjan Kissoon; Kimberly Peterson; Nathan R Selden; Robert C Tasker; Karen A Tong; Monica S Vavilala; Mark S Wainwright; Craig R Warden Journal: Pediatr Crit Care Med Date: 2012-01 Impact factor: 3.624
Authors: Juan Pablo de Rivero Vaccari; Frank Brand; Stephanie Adamczak; Stephanie W Lee; Jon Perez-Barcena; Michael Y Wang; M Ross Bullock; W Dalton Dietrich; Robert W Keane Journal: J Neurochem Date: 2015-03-01 Impact factor: 5.372
Authors: Jon Perez-Barcena; Javier Ibáñez; Marta Brell; Catalina Crespí; Guiem Frontera; Juan Antonio Llompart-Pou; Javier Homar; Josep María Abadal Journal: Crit Care Med Date: 2011-03 Impact factor: 7.598
Authors: Margaret A Satchell; Yichen Lai; Patrick M Kochanek; Stephen R Wisniewski; Ericka L Fink; Neal A Siedberg; Rachel P Berger; Steven T DeKosky; P David Adelson; Robert S B Clark Journal: J Cereb Blood Flow Metab Date: 2005-07 Impact factor: 6.200
Authors: Ido Yatsiv; Maria C Morganti-Kossmann; Daniel Perez; Charles A Dinarello; Daniela Novick; Menachem Rubinstein; Viviane I Otto; Mario Rancan; Thomas Kossmann; Claudio A Redaelli; Otmar Trentz; Esther Shohami; Philip F Stahel Journal: J Cereb Blood Flow Metab Date: 2002-08 Impact factor: 6.200
Authors: Stephanie Adamczak; Gordon Dale; Juan Pablo de Rivero Vaccari; M Ross Bullock; W Dalton Dietrich; Robert W Keane Journal: J Neurosurg Date: 2012-10-12 Impact factor: 5.115
Authors: Juan Pablo de Rivero Vaccari; George Lotocki; Ofelia F Alonso; Helen M Bramlett; W Dalton Dietrich; Robert W Keane Journal: J Cereb Blood Flow Metab Date: 2009-04-29 Impact factor: 6.200
Authors: Jacqueline F Moreau; Ericka L Fink; Mary E Hartman; Derek C Angus; Michael J Bell; Walter T Linde-Zwirble; R Scott Watson Journal: Pediatr Crit Care Med Date: 2013-10 Impact factor: 3.624
Authors: Dennis W Simon; Rajesh K Aneja; Henry Alexander; Michael J Bell; Hülya Bayır; Patrick M Kochanek; Robert S B Clark Journal: J Neurotrauma Date: 2017-08-22 Impact factor: 5.269
Authors: Sheryl E Arambula; Erin L Reinl; Nagat El Demerdash; Margaret M McCarthy; Courtney L Robertson Journal: Exp Neurol Date: 2019-03-02 Impact factor: 5.330
Authors: Han-Sen Xiao; Qian Xie; Jia-Yu Zhong; Bisanga Gerald Rukundo; Xiao-Long He; Ya-Li Qu; Hong Cao Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2018-06-20
Authors: Stephanie W Lee; Shyam Gajavelli; Markus S Spurlock; Cody Andreoni; Juan Pablo de Rivero Vaccari; M Ross Bullock; Robert W Keane; W Dalton Dietrich Journal: J Neurotrauma Date: 2018-04-02 Impact factor: 5.269